| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC2681 |
| Trial ID | NCT04878484 |
| Disease | Advanced Solid Tumor |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | TCRT-ESO-A2 |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Withdrawn |
| Title | A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, and Activity of TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors |
| Year | 2021 |
| Country | United Kingdom |
| Company sponsor | Athenex, Inc. |
| Other ID(s) | AX TCRT 001 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||
|
|||||||||||